Back
Sonnet BioTherapeutics Holdings Quote, Financials, Valuation and Earnings
My #1 Coin is...
All the details are on the next page.
Sell
33
SONN
Sonnet BioTherapeutics Holdings
Last Price:
1.88
Seasonality Move:
-16.32%
7 Day Trial
ALL ACCESS PASS
$
7
The little-known AI stock you need to read about now...
Get the name - FREE.Sonnet BioTherapeutics Holdings Price Quote
$1.88
+0.02 (+-2.08%)
(Updated: May 4, 2024 at 6:37 AM ET)
Sonnet BioTherapeutics Holdings Key Stats
Sell
33
Sonnet BioTherapeutics Holdings (SONN)
is a Sell
Day range:
$1.81 - $1.97
52-week range:
$1.08 - $26.40
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
27.49
P/B ratio:
2.22%
Volume:
7.5K
Avg. volume:
23.6K
1-year change:
-66.17%
Market cap:
$5.7M
Revenue:
$147.8K
EPS:
$-12.75
How Much Does Sonnet BioTherapeutics Holdings Make?
-
How Much Are Sonnet BioTherapeutics Holdings's Sales Annually?
SONN Revenues are $147.8K -
How Much Profit Does Sonnet BioTherapeutics Holdings's Make A Year?
SONN net income is -$18.8M
Is Sonnet BioTherapeutics Holdings Growing As A Company?
-
What Is Sonnet BioTherapeutics Holdings's Growth Rate Quarterly?
Quarterly YoY revenue growth is -0.5% -
What Is Sonnet BioTherapeutics Holdings's EPS Quarterly YoY Growth Rate?
Quarterly, year-over-year diluted EPS growth rate is 0%
Sonnet BioTherapeutics Holdings Stock Price Performance
-
Did Sonnet BioTherapeutics Holdings Stock Go Up Last Month?
Sonnet BioTherapeutics Holdings share price went down by -4.9% last month -
Did SONN's Share Price Rise Over The Last Year?
SONN share price fell by -66.17% over the past 1 year
What Is Sonnet BioTherapeutics Holdings 52-Week High & Low?
-
What Is Sonnet BioTherapeutics Holdings’s 52-Week High Share Price?
Sonnet BioTherapeutics Holdings has traded as high as $26.40 over the past 52 weeks -
What Is Sonnet BioTherapeutics Holdings’s 52-Week Low Share Price?
Sonnet BioTherapeutics Holdings has traded as low as $1.08 over the past 52 weeks
Sonnet BioTherapeutics Holdings Price To Free Cash Flow
Data Unavailable
Is It Risky To Buy Sonnet BioTherapeutics Holdings?
-
How Much Debt Does Sonnet BioTherapeutics Holdings Have?
Total long term debt quarterly is $0 -
How Much Cash Does Sonnet BioTherapeutics Holdings Have?
Cash and short term investments quarterly total is $3M -
What Is Sonnet BioTherapeutics Holdings’s Book Value Per Share?
Book value per share is 0.84
Is Sonnet BioTherapeutics Holdings Cash Flow Positive?
-
What Is SONN Cash Flow From Operations?
Cash flow from operations (TTM) is -$18.5M -
What Is Sonnet BioTherapeutics Holdings’s Cash Flow From Financing?
Cash flow from financing (TTM) is $20.3M -
What Is Sonnet BioTherapeutics Holdings’s Cash Flow From Investing?
Cash flow from investing (TTM) is $0
Sonnet BioTherapeutics Holdings Return On Invested Capital
-
Is Management Doing A Good Job?
SONN return on invested capital is -951.52% -
What Is Sonnet BioTherapeutics Holdings Return On Assets?
ROA measures how assets are converting to revenues and is -185.11% -
What Is SONN Return On Equity?
ROE is a measure of profitability and is -951.71%
Sonnet BioTherapeutics Holdings Earnings Date & Stock Price
-
What Is Sonnet BioTherapeutics Holdings's Stock Price Today?
A single share of SONN can be purchased today for 1.86 -
What Is Sonnet BioTherapeutics Holdings’s Stock Symbol?
Sonnet BioTherapeutics Holdings trades on the nasdaq under the ticker symbol: SONN -
When Is Sonnet BioTherapeutics Holdings’s Next Earnings Date?
The next quarterly earnings date for Sonnet BioTherapeutics Holdings is scheduled on May 10, 2024 -
When Is SONN's next ex-dividend date?
Sonnet BioTherapeutics Holdings's next ex-dividend date is May 4, 2024 -
How To Buy Sonnet BioTherapeutics Holdings Stock?
You can buy Sonnet BioTherapeutics Holdings shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
Sonnet BioTherapeutics Holdings Competitors
-
Who Are Sonnet BioTherapeutics Holdings's Competitors?
Below is a list of companies who compete with Sonnet BioTherapeutics Holdings or are related in some way:
Sonnet BioTherapeutics Holdings Dividend Yield
Data Unavailable
Sonnet BioTherapeutics Holdings Analyst Estimates
| YoY Growth | Past Surprise | |
|---|---|---|
| EPS: | 0% | 67.02% |
| Revenue: | -50% | 55.25% |
Analyst Recommendations
| Buy Recommendations: | 4 |
|---|---|
| Hold Recommendations: | 0 |
| Sell Recommendations: | 0 |
| Price Target: | 12.50 |
| Upside from Last Price: | 571.9% |